Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity by tobacco smoke

Neuropharmacology. 1990 Mar;29(3):311-4. doi: 10.1016/0028-3908(90)90019-n.

Abstract

Several epidemiological studies have indicated that there may be an inverse relationship between smoking and Parkinson's disease. The purpose of this study was to determine whether chronic exposure to cigarette smoke alters the parkinsonian-like neurochemical changes caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice. Following 4 weeks of brief, intermittent exposure to smoke, mice were treated with MPTP, 10 mg/kg. Smoke exposure was found to reduce the decrease in striatal dopamine and metabolite levels caused by MPTP. Although smoke exposure inhibited cerebral MAO-B activity, tissues from smoke-treated mice were able to metabolize MPTP in a normal fashion. This suggests that inhibition of cerebral MAO may not be a major mechanism for the apparent protective effect of cigarette smoke.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / analogs & derivatives*
  • 3,4-Dihydroxyphenylacetic Acid / metabolism
  • Animals
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Dopamine / metabolism
  • Homovanillic Acid / metabolism
  • Liver / enzymology
  • MPTP Poisoning
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Monoamine Oxidase / metabolism
  • Nervous System Diseases / chemically induced*
  • Nervous System Diseases / metabolism
  • Smoking / metabolism*

Substances

  • 3,4-Dihydroxyphenylacetic Acid
  • 1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Monoamine Oxidase
  • Dopamine
  • Homovanillic Acid